華海藥業(600521.SH)一季度扣非淨利潤預降15%-25%
格隆匯 4 月 8日丨華海藥業(600521.SH)公佈,公司2021年一季度實現歸屬於上市公司股東的淨利潤預計在2.42億元至2.65億元之間,與上年同期(法定披露數據)相比增長約10%到20%。
公司2021年一季度業績預增主要是由於2021年一季度公司出售了參股公司杭州多禧生物科技有限公司3.8597%的股權,預計增加公司2021年度投資收益約人民幣9000萬元至9800萬元(税前)(此數據未經審計,對公司的影響金額最終以審計數據為準)。
公司2021年一季度歸屬於上市公司股東的扣除非經常性損益的淨利潤預計在1.48億元至1.68億元之間,與上年同期(法定披露數據)相比下降約15%到25%。
2021年一季度歸屬於上市公司股東的扣除非經常性損益的淨利潤有所下滑,主要受原料藥產品銷售結構變化、美國製劑業務持續受FDA禁令影響以及公司研發投入的不斷加大所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.